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intervention letters on the recurrence of exceptions, multiple
regression models were developed using prescriber-level mean
time (in days) between exceptions. In addition, the effect on
medical costs and utilization was measured for a subset of data
using a pre-post design with a control group. Pre-post periods
were deﬁned as 120 days before and after the date of interven-
tion letters dated between May 1 and August 31, 2003. Controls
were selected by matching to intervention cases using the propen-
sity score methods. Sensitivity analysis was performed using
varying time windows and bootstrap samples. Outcomes related
to PMPM inpatient admissions, emergency room visits, and
physician ofﬁce visits were analyzed. RESULTS: Of 51,214 pre-
scribers who had two or more exceptions during the 23-month
time period, 6233 (12%) were randomly selected to receive inter-
vention letters (ranging from one to 19). Model coefﬁcients indi-
cated that the time to exception was longer by 6.5 days (p <
0.001) as prescribers received additional intervention letters,
after adjusting for the number of exceptions, severity level, and
average patient age. There were no signiﬁcant differences in med-
ication costs from pre to post time periods, or between groups
(study vs. control). However, the study group had fewer PMPM
inpatient admissions and emergency room visits. CONCLU-
SIONS: Retrospective drug utilization review processes can have
a positive effect in delaying next exceptions for prescribers and
reducing utilization of health care services.
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OBJECTIVE: Budget impact analysis (BIA) evaluates ﬁnancial
impacts of new technologies; it provides valuable information to
decision-makers with a budget concern. This study proposes a
dynamic model to incorporate variations in patients mix and
drug prices over time in BIA. METHODS: The dynamic model
is an inhomogeneous Markov Chain model. It contains three
Markov states categorized by whether a patient’s illness was
treated with a generic drug, an existing brand-name drug, or the
new brand-name drug. At each cycle, the model modiﬁes the
patient cohort by accounting for newly diagnosed incident cases
and exiting cases due to cure or death. Also considered is a pos-
sible difference in the preference of treatment selection between
the current and newly diagnosed patients. We conducted BIA on
a simulated data using the Bayesian approach and presented the
results in a probabilistic plot similar to the cost-effectiveness
acceptability curve. A case study comparing the budget impact
of including versus excluding a new drug in a health plan was
used to demonstrate our method. The case study assumes the
perspective of a payer and a time frame of ﬁve years. RESULTS:
Results based on the simulated data showed that adding the 
new drug to the plan is associated with a budget increase in the
short run but would reduce the budget in the long run. The prob-
ability that including the new drug would increase in the budget
by 10% is 9%, 26% in a one- and two-year study timeframe,
and it becomes cost neutral in the ﬁve-year timeframe. CON-
CLUSIONS: The proposed model provides a powerful frame-
work to examine the time-varying parameters in BIA and
generates estimates that better reﬂect health care market in the
real world.
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OBJECTIVE: To capture patient compliance data on a pre-
scribed concomitant medication of an international product 
registry. The data needed to be collected in an accurate, timely,
non-burdensome, and cost-effective manner. METHODS:
Several patient compliance measurement options were consid-
ered but not selected including: physician ofﬁce surveys, tele-
phone surveys, and proxy responses. We chose the Medication
Electronic Monitoring Systems (MEMS), which is a standard
plastic vial, and a cap for the vial that contains a micro-
electronic circuit that records times when the cap is opened 
and closed. MEMS bottles and caps were given to participating
clinicians with speciﬁc instructions for distribution to registry
participants. MEMS were to be ﬁlled with a full 6-month pre-
scription of the concomitant medication and distributed to
patients at discharge. Patients were to be instructed to complete
the prescribed regimen and received instructions on the use and
purpose of the MEMS. They also were to receive written instruc-
tions on returning the MEMS to their clinician after 6 months.
The clinicians were to return the MEMS caps to a centralized
data processing center in the United States for analysis.
RESULTS: MEMS were distributed to 707 patients, by 43 physi-
cians, in 9 countries on 6 continents. The cost of distribution
(including devices and mailings) was approximately $100.00 per
patient. Delays in receiving MEMS caps from patients in a timely
manner were experienced, as were delays in receiving MEMS
caps from sites. Of the 240 MEMS devices administered, 26%
returned the cap for analysis and 24% of the MEMS caps yielded
analyzable data. CONCLUSION: Compared to other methods
of collecting compliance data on a large international scale,
MEMS provided a non-burdensome manner for collecting data.
However, the low return rate indicates that this process must be
monitored closely to maximize results, minimize costs and to
ensure that patient utilization does not vary.
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OBJECTIVE: This study compares two compliance measure-
ments, a telephone patient-reported survey and the Medication
Electronic Monitoring System (MEMS), for a 12-month inter-
national registry studying re-intervention rates for interventional
cardiology. METHODS: Patients were prescribed a 6-month
anti-platelet drug regimen upon discharge from the hospital.
Drug was supplied to all patients in a MEMS bottle, which con-
tained an electronic cap that recorded internally the date and
time the bottle was opened. At the end of six months, patients
were to return the empty bottle to their provider for analysis.
Patients included in this study were also contacted via telephone
quarterly to recall their medication compliance status. The agree-
ment between the two methods was evaluated using the weighted
Cohen’s kappa statistic (Kw). RESULTS: Of the 778 patients
enrolled in the registry, 707 were given MEMS devices, and of
those patients, 642 have reached the 6-month endpoint. A total
